
Lantheus Holdings (LNTH) Stock Forecast & Price Target
Lantheus Holdings (LNTH) Analyst Ratings
Bulls say
Lantheus Holdings is a radiopharmaceutical-focused company that produces and markets products for cancer and disease detection and monitoring. The company's recent FDA approvals for PYLARIFY TruVu and its tentative approval for PNT2003 demonstrate its strong product pipeline and potential for growth. Additionally, the company's focus on strategic partnerships and expansion into international markets provide further opportunities for revenue growth. However, there are also risks related to regulation and reimbursement, as well as potential disruptions to the company's manufacturing and distribution networks. As a financial analyst, the positive outlook for this stock is based on the potential for continued revenue growth and a focus on innovation and expansion into new markets, which could drive shareholder value in the long term.
Bears say
Lantheus Holdings is currently facing challenges due to pricing declines and strong competition in the oncology market, which is causing a decline in revenue. Additionally, while the company has a promising pipeline in the Alzheimer's diagnostic market, it may still be a few years before they see significant contribution from these products. With limited short-term catalysts and a negative outlook for the oncology market, the stock may continue to underperform in the near future.
This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.
Lantheus Holdings (LNTH) Analyst Forecast & Price Prediction
Start investing in Lantheus Holdings (LNTH)
Order type
Buy in
Order amount
Est. shares
0 shares